The Amyloidosis Channel is supported through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESC 2026 | Transitioning anselamimab into clinical practice: key challenges and opportunities
Xiaowen Wang, MD, Brigham and Women’s Hospital, Boston, MA, discusses the need for longer-term data to confirm the durability of anselamimab treatment benefits in patients with light-chain (AL) amyloidosis. Dr Wang highlights ongoing extension studies and notes that further data are needed to assess potential improvements in quality of life and functional capacity. This interview took place during the 2026 European Society of Cardiology (ESC) Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
